Compare VRAX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | PRPO |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 44.4M |
| IPO Year | 2021 | 2000 |
| Metric | VRAX | PRPO |
|---|---|---|
| Price | $0.16 | $25.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 155.4K | 10.2K |
| Earning Date | 03-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,532,000.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $0.15 | $4.90 |
| 52 Week High | $1.34 | $29.53 |
| Indicator | VRAX | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 44.51 |
| Support Level | N/A | $22.58 |
| Resistance Level | $0.25 | $26.16 |
| Average True Range (ATR) | 0.02 | 1.46 |
| MACD | -0.00 | -0.37 |
| Stochastic Oscillator | 13.64 | 0.00 |
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.